Cellyan Biotechnology Co. Ltd Class A (HKPD)
NASDAQ: HKPDHealth CareOther PharmaceuticalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HKPD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.40M
- EPS (TTM)
- -$1.38
- Dividend yield
- None
- 52-week range
- 1.20 – 22.10
- Day range
- 1.29 – 1.41
- Volume / Avg
- 93.94K / 183.65K
- Beta
- —
- Shares outstanding
- 2.11M
52-week range
HKPD stock today
Cellyan Biotechnology (HKPD) closed at $1.38 on Nov 20, up 2.60% (+$0.035), versus the S&P 500's 3.70% decline. Shares are 93.8% below their 52-week high of $22.10 and 15.0% above the 52-week low of $1.20, near the bottom of the past year's range. Cellyan Biotechnology has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cellyan Biotechnology
Company profileCellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services.
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- CEO
- Mr. Chenyu Liang
- Headquarters
- Yau Tong
- Employees
- 11
- IPO year
- 2025
- Website
- 9zt.hk
Financial highlights
Full financialsIn fiscal 2025, Cellyan Biotechnology generated $20.3 million in revenue, up 21.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Cellyan Biotechnology reported a net loss of $27,056, compared with net income of $1.3 million a year earlier. Gross margin was 11.9% (down from 21.3%) and operating margin -11.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $20.31M | $16.69M | $12.56M |
| Growth | +21.72% | +32.91% | — |
| Net income | $-27.06K | $1.33M | $998.20K |
| EPS (diluted) | $-0.003 | $0.18 | $0.146 |
HKPD news
All HKPD newsCellyan Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MEDSDataMeds AI Inc. | 1.34 | +84.14% | $7.67M | vs HKPD |
| COSMCosmos Health Inc. | 2.81 | -2.09% | $14.14M | vs HKPD |
| ESYNEnerSyn Global Inc. | 1.11 | -0.89% | $37.44M | vs HKPD |
| NUSNu Skin Enterprises Inc. | 3.80 | +0.80% | $184.98M | vs HKPD |
| HLFHerbalife Ltd. | 15.53 | -0.26% | $1.63B | vs HKPD |
| CAHCardinal Health Inc. | 272.81 | +0.17% | $63.06B | vs HKPD |
| CORCencora Inc. | 339.09 | -0.63% | $64.71B | vs HKPD |
| MCKMcKesson Corporation | 1,069.43 | +0.68% | $123.47B | vs HKPD |
Indexes, lists and sector
Cellyan Biotechnology stock FAQ
What is Cellyan Biotechnology's stock price today?
HKPD last traded at $1.38 as of Nov 20, 4:00 PM EST, up 2.60% on the day. Prices are delayed at least 15 minutes.
Does Cellyan Biotechnology pay a dividend?
No. Cellyan Biotechnology does not currently pay a regular cash dividend.
Who is Cellyan Biotechnology's CEO?
Mr. Chenyu Liang is the chief executive officer of Cellyan Biotechnology Co. Ltd Class A, which has about 11 employees.
Has HKPD ever split its stock?
Yes. The most recent HKPD stock split was a 1-for-20 split on Oct 26, 2026.
What is the HKPD 52-week high?
The 52-week high for HKPD is $22.10 and the 52-week low is $1.20. The stock is currently 93.8% below its high.